482d: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:482d.gif|left|200px]]
{{Seed}}
[[Image:482d.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_482d|  PDB=482d  |  SCENE=  }}  
{{STRUCTURE_482d|  PDB=482d  |  SCENE=  }}  


'''RELEASE OF THE CYANO MOIETY IN THE CRYSTAL STRUCTURE OF N-CYANOMETHYL-N-(2-METHOXYETHYL)-DAUNOMYCIN COMPLEXED WITH D(CGATCG)'''
===RELEASE OF THE CYANO MOIETY IN THE CRYSTAL STRUCTURE OF N-CYANOMETHYL-N-(2-METHOXYETHYL)-DAUNOMYCIN COMPLEXED WITH D(CGATCG)===




==Overview==
<!--
Doxorubicin is among the most widely used anthracycline in cancer chemotherapy. In an attempt to avoid the cardiotoxicity and drug resistance of doxorubicin therapy, several analogues were synthesized. The cyanomorpholinyl derivative is the most cytotoxic. They differ greatly from their parent compound in their biological and pharmacological properties, inducing cross-links in drug DNA complexes. The present study concerns N-cyanomethyl-N-(2-methoxyethyl)-daunomycin (CMDa), a synthetic analogue of cyanomorpholino-daunomycin. Compared to doxorubicin, CMDa displays a cytotoxic activity on L1210 leukemia cells at higher concentration but is effective on doxorubicin resistant cells. The results of fluorescence quenching experiments as well as the melting temperature (DeltaTm = 7.5 degrees C) studies are consistent with a drug molecule which intercalates between the DNA base pairs and stabilizes the DNA double helix. The crystal structure of CMDa complexed to the hexanucleotide d(CGATCG) has been determined at 1.5 A resolution. The complex crystallizes in the space group P41212 and is similar to other anthracycline-hexanucleotide complexes. In the crystal state, the observed densities indicate the formation of N-hydroxymethyl-N-(2-methoxyethyl)-daunomycin (HMDa) with the release of the cyano moiety without DNA alkylation. The formation of this degradation compound is discussed in relation with other drug modifications when binding to DNA. Comparison with two other drug-DNA crystal structures suggests a correlation between a slight change in DNA conformation and the nature of the amino sugar substituents at the N3' position located in the minor groove.
The line below this paragraph, {{ABSTRACT_PUBMED_10632715}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 10632715 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_10632715}}


==About this Structure==
==About this Structure==
Line 30: Line 34:
[[Category: Double helix]]
[[Category: Double helix]]
[[Category: Right handed dna]]
[[Category: Right handed dna]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 22:20:05 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Jul 3 13:25:49 2008''

Revision as of 13:25, 3 July 2008

File:482d.png

Template:STRUCTURE 482d

RELEASE OF THE CYANO MOIETY IN THE CRYSTAL STRUCTURE OF N-CYANOMETHYL-N-(2-METHOXYETHYL)-DAUNOMYCIN COMPLEXED WITH D(CGATCG)RELEASE OF THE CYANO MOIETY IN THE CRYSTAL STRUCTURE OF N-CYANOMETHYL-N-(2-METHOXYETHYL)-DAUNOMYCIN COMPLEXED WITH D(CGATCG)

Template:ABSTRACT PUBMED 10632715

About this StructureAbout this Structure

Full crystallographic information is available from OCA.

ReferenceReference

Release of the cyano moiety in the crystal structure of N-cyanomethyl-N-(2-methoxyethyl)-daunomycin complexed with d(CGATCG)., Saminadin P, Dautant A, Mondon M, Langlois D'estaintot B, Courseille C, Precigoux G, Eur J Biochem. 2000 Jan;267(2):457-64. PMID:10632715

Page seeded by OCA on Thu Jul 3 13:25:49 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA